The sensitivity of primary CLL cells to the cytotoxic effects of ONC‐212, compared to PBMC fractions from healthy individuals or T‐cells from CLL patients (Figures 1C and 1D), suggests that ONC‐212 may also specifically target the leukemic cells, in a manner similar to venetoclax and ibrutinib [40, 41, 42], due to the dependence of the CLL cells on signaling down‐stream of the BCR and on the BCL2‐family proteins. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.